Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LJM716 + Cetuximab in HNSCC
NCT02143622Phase 2Withdrawn
- Sponsor
- Novartis
- Start
- Mar 2015
- Primary completion
- Aug 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
A Phase 2 trial of elgemtumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Novartis. Planned start Mar 2015; status: withdrawn.
02
Drugs
elgemtumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT02143622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02143622.